Furthest along
13 approved
13 in Phase 3
Drugs
72
in active trials · 172 in all
Trials
185 active
593 since 2021
Drugs72
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Approved | Nov 2026soonPhase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Fallopian Tube Cancer, Primary Peritoneal Cancer and 9 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Approved | Nov 2026soonPhase 3 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Atopic Dermatitis, Rheumatoid Arthritis and 13 more | ||||
| Open drug page | |||||
BCL-2 inhibitor |
Approved | Nov 2026soonPhase 2 trial completes | |||
| How it works | Blocks BCL-2 | ||||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Multiple Myeloma, Acute Myeloid Leukemia and 10 more | ||||
| Open drug page | |||||
Atypical antipsychotic |
Approved | 15 Dec 2026soonPhase 3 trial completes | |||
| Next date | 15 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Schizophrenia, Depression and 1 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | Feb 2027Phase 1/2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm and 1 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | Mar 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Crohn's Disease, Ulcerative Colitis and 7 more | ||||
| Open drug page | |||||
Calcitonin gene-related peptide receptor antagonist |
Approved | May 2027Phase 3 trial completes | |||
| Next date | May 2027 · Phase 3 trial completes | ||||
| Also tested for | Migraine | ||||
| Open drug page | |||||
Acetylcholine release Inhibitor; neuromuscular blocker |
Approved | Jun 2027Phase 4 trial completes | |||
| Next date | Jun 2027 · Phase 4 trial completes | ||||
| Also tested for | Glabellar Lines, Jawline and Neck Appearance and 1 more | ||||
| Open drug page | |||||
Gonadotropin releasing hormone receptor antagonist |
Approved | Jul 2027Phase 3 trial completes | |||
| Next date | Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Endometriosis | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | Sep 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Rheumatoid Arthritis, Juvenile Psoriatic Arthritis and 1 more | ||||
| Open drug page | |||||
C-Met-targeted antibody-drug conjugate |
Approved | Feb 2028Phase 2 trial completes | |||
| Next date | Feb 2028 · Phase 2 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, c-MET and 2 more | ||||
| Open drug page | |||||
Calcitonin gene-related peptide receptor antagonist |
Approved | Mar 2028Phase 3 trial completes | |||
| Next date | Mar 2028 · Phase 3 trial completes | ||||
| Also tested for | Migraine Prophylaxis, Episodic Migraine and 2 more | ||||
| Open drug page | |||||
Mu-Opioid receptor agonist |
Approved | Dec 2032Phase 3 trial completes | |||
| Next date | Dec 2032 · Phase 3 trial completes | ||||
| Also tested for | Irritable Bowel Syndrome | ||||
| Open drug page | |||||
PD-1 antibody |
Phase 2/3 | Nov 2026soonPhase 2 trial completes | |||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumors Cancer, Advanced Solid Tumors and 19 more | ||||
| Open drug page | |||||
GARP/TGF-beta antibody |
Phase 2/3 | Nov 2026soonPhase 2 trial completes | |||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Advanced Solid Tumors Cancer and 2 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | Dec 2026Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Hidradenitis Suppurativa, Atopic Dermatitis and 4 more | ||||
| Open drug page | |||||
— |
Phase 3 | 31 Dec 2026Phase 1 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Myelofibrosis (MF), Myeloproliferative Neoplasm | ||||
| Open drug page | |||||
Gene therapy substances |
Phase 3 | Dec 2026Phase 2/3 trial completes | |||
| How it works | A gene therapy | ||||
| Next date | Dec 2026 · Phase 2/3 trial completes | ||||
| Also tested for | Neovascular Age-Related Macular Degeneration (nAMD), AMD and 11 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | Dec 2026Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Colorectal Cancer, Non-Small Cell Lung Cancer and 27 more | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
RemeGen |
Phase 3 | 12 May 2027Phase 2/3 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 12 May 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Solid Tumor and 6 more | ||||
| Open drug page | |||||
No drugs match “”.
SEC filings54
Since Jan 2024 · All on SEC.gov- 2 NovChanged a director or officer · SEC 8-K
- 30 OctReported quarterly results · SEC 8-K
- 15 OctChanged a director or officer · SEC 8-K
- 5 OctReported quarterly results · SEC 8-K
- 3 SepMade a public disclosure · SEC 8-K
- 18 AugReported other events · SEC 8-K
- 6 AugOffered new securities · 1 prospectus (424B5)
- 5 AugReported other events · SEC 8-K
- 4 AugOffered new securities · 1 prospectus (424B5)
- 31 JulReported quarterly results · SEC 8-K
- 6 JulReported quarterly results · SEC 8-K
- 22 JunMade a public disclosure · SEC 8-K
- 12 MayFiled a report · SEC 8-K
- 29 AprReported quarterly results · SEC 8-K
- 3 AprReported quarterly results · SEC 8-K
- 4 MarReported other events · SEC 8-K
- 26 FebOffered new securities · 1 prospectus (424B5)
- 26 FebReported other events · SEC 8-K
- 24 FebOffered new securities · 1 prospectus (424B5)
- 4 FebReported quarterly results · SEC 8-K
- 7 JanReported quarterly results · SEC 8-K
- 31 Oct 2025Reported quarterly results · SEC 8-K
- 3 Oct 2025Reported quarterly results · SEC 8-K
- 11 Sep 2025Made a public disclosure · SEC 8-K
- 31 Jul 2025Reported quarterly results · SEC 8-K
- 3 Jul 2025Reported quarterly results · SEC 8-K
- 13 May 2025Changed a director or officer · SEC 8-K
- 25 Apr 2025Reported quarterly results · SEC 8-K
- 3 Apr 2025Reported quarterly results · SEC 8-K
- 26 Feb 2025Reported other events · SEC 8-K
- 20 Feb 2025Offered new securities · 1 prospectus (424B5)
- 19 Feb 2025Reported other events · SEC 8-K
- 18 Feb 2025Offered new securities · 1 prospectus (424B5)
- 14 Feb 2025Changed a director or officer and made a public disclosure · SEC 8-K
- 5 Feb 2025Reported other events · SEC 8-K
- 31 Jan 2025Reported quarterly results · SEC 8-K
- 10 Jan 2025Filed a report · SEC 8-K
- 6 Jan 2025Reported quarterly results · SEC 8-K
- 13 Dec 2024Changed a director or officer · SEC 8-K
- 30 Oct 2024Reported quarterly results · SEC 8-K
- 3 Oct 2024Reported quarterly results · SEC 8-K
- 10 Sep 2024Filed a report · SEC 8-K
- 25 Jul 2024Reported quarterly results · SEC 8-K
- 3 Jul 2024Reported quarterly results · SEC 8-K
- 8 May 2024Changed a director or officer · SEC 8-K
- 26 Apr 2024Reported quarterly results · SEC 8-K
- 3 Apr 2024Reported quarterly results · SEC 8-K
- 26 Feb 2024Offered new securities · 1 prospectus (424B5)
- 26 Feb 2024Reported other events · SEC 8-K
- 21 Feb 2024Offered new securities · 1 prospectus (424B5)
- 20 Feb 2024Changed a director or officer and made a public disclosure · SEC 8-K
- 12 Feb 2024Made a public disclosure · SEC 8-K
- 2 Feb 2024Reported quarterly results · SEC 8-K
- 5 Jan 2024Reported quarterly results · SEC 8-K
About
- No active trial
- 100 other drugs
- Registry names
- 3 names in ClinicalTrials.gov AbbVie
AbbVie (prior sponsor, Abbott)
Capstan Therapeutics - Sources
- ClinicalTrials.gov updated 16 Nov 2026 · SEC filings Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev